From the Editor

Good Abi, Bad Abi - Charles Ryan

Charles Ryan
July 11, 2018

Hormonal signaling is an intriguing process with a lot of redundancy, promiscuity and feedback. Androgen metabolism is particularly complicated and likely reflects the absolute necessity of intact hormonal signaling for mammalian evolution. I have spent over 15 years studying many aspects of prostate cancer but probably the two most prominent facets of my research life relate to the development of treatments like abiraterone for mCRPC but also the study of the measure of hormones, their signaling patterns and its relationship to outcome in CRPC.

READ MORE PREVIOUS ARTICLES

Dr. Charles J. Ryan, MD

Charles J. Ryan, MD

Charles J. Ryan, MD is Professor of Clinical Medicine and Urology and the Clinical Program Leader for Genitourinary Medical Oncology at the UCSF Helen Diller Family Comprehensive Cancer Center. He received his MD from the University of Wisconsin in Madison and completed his residency in internal medicine at the University of Wisconsin Hospital and Clinics, where he also served as Chief Resident. He completed a fellowship in medical oncology in the Department of Medicine at Memorial Sloan-Kettering Cancer Center and the Joan and Sanford I. Weill Medical College of Cornell University in New York.

Video Lectures
State-of-the-industry video lectures by leading urology experts
Conference Highlights
Recent data from conferences worldwide

ASCO 2018 Prostate Cancer

AUA 2018 Prostate Cancer

EAU 2018 Prostate Cancer

ASCO GU 2018 Prostate Cancer

SUO 2017 - Prostate Cancer

SIU 2017 Prostate Cancer

ESMO 2017 Prostate Cancer

CUA 2017

TAT-10

ASCO 2017 Prostate Cancer

AUA 2016 Prostate cancer

ASCO GU 2016 Prostate Cancer

ASCO GU 2016 mCRPC Treatment